论文部分内容阅读
AIM:To analyze prognostic factors for survival after transarterial chemoembolization(TACE)combined with microwave ablation(MWA)for hepatocellular carcinoma(HCC).METHODS:Clinical data of 86 patients who underwent TACE combined with MWA between January 2006and December 2013 were retrospectively analyzed in this study.Survival curves were detected using log-rank test.Univariate analysis was performed using log-rank test with respect to 13 prognostic factors affecting survival.All statistically significant prognostic factors identified by univariate analysis were entered into a Cox proportion hazards regression model to identify independent predictors of survival.P values were two-sided and P<0.05 was considered statistically significant.RESULTS:Median follow-up time was 47.6 mo,andmedian survival time of enrolled patients was 21.5 mo.The 1-,2-,3-and 5-year overall survival rates were72.1%,44.1%,31.4%and 13.9%,respectively.Tumor size(χ2=14.999,P=0.000),Barcelona Clinic Liver Cancer(BCLC)stage(χ2=29.765,P=0.000),ChildPugh class(χ2=51.820,P=0.000),portal vein tumor thrombus(PVTT)(χ2=43.086,P=0.000),arteriovenous fistula(χ2=29.791,P=0.000),MWA therapy times(χ2=12.920,P=0.002),Eastern Cooperative Oncology Group(ECOG)score(χ2=28.660,P=0.000)and targeted drug usage(χ2=10.901,P=0.001)were found to be significantly associated with overall survival by univariate analysis.Multivariate analysis identified that tumor size(95%CI:1.608-4.962,P=0.000),BCLC stage(95%CI:1.016-2.208,P=0.020),PVTT(95%CI:2.062-9.068,P=0.000),MWA therapy times(95%CI:0.402-0.745,P=0.000),ECOG score(95%CI:1.012-3.053,P=0.045)and targeted drug usage(95%CI:1.335-3.143,P=0.001)were independent prognostic factors associated with overall survival.CONCLUSION:Superior performance status,MWA treatment and targeted drug were favorable factors,and large HCC,PVTT and advanced BCLC stage were risk factors for survival after TACE-MWA for HCC.
AIM: To analyze prognostic factors for survival after transarterial chemoembolization (TACE) combined with microwave ablation (MWA) for hepatocellular carcinoma (HCC). METHODS: Clinical data of 86 patients who underwent TACE combined with MWA between January 2006 and December 2013 were retrospectively analyzed in this study. Survival curves were detected using log-rank test. Univariate analysis was performed using log-rank test with respect to 13 prognostic factors affecting survival. Anomalies significant prognostic factors identified by univariate analysis were entered into a Cox proportion hazards regression model to P <0.05 was found significant significant .RESULTS: Median follow-up time was 47.6 mo, and median survival time of enrolled patients was 21.5 mo. 1-, 2-, 3 -and 5-year overall survival rates were 72.1%, 44.1%, 31.4% and 13.9% respectively. Tumor size (χ2 = 14.999, P = 0.000), Barcelona Clinic Liver Cancer (χ2 = 29.765, P = 0.000), ChildPugh class (χ2 = 51.820, P = 0.000), portal vein tumor thrombus (PVTT) ), MWA therapy times (χ2 = 12.920, P = 0.002), Eastern Cooperative Oncology Group (ECOG) score (χ2 = 28.660, P = 0.000) and targeted drug usage associated with overall survival by univariate analysis. Multivariate analysis identified that tumor size (95% CI: 1.608-4.962, P = 0.000), BCLC stage (95% CI: 1.012-3.053, P = 0.045) and targeted drug usage (95% CI: 0.402-0.745, P = 0.000) 1.335-3.143, P = 0.001) were independent prognostic factors associated with overall survival. CONCLUSION: Superior performance status, MWA treatment and targeted drug were favorable factors, and large HCC, PVTT and advanced BCLC stage were risk factors for survival after TACE-MWA for HCC.